More positive data for Zolgensma in spinal muscular atrophy

24 March 2020
novartis_tower_large

Data published at a virtual Clinical Trial Session, conducted by the Muscular Dystrophy Association (MDA), show Zolgensma (onasemnogene abeparvovec-xioi) produced significant benefit to people with spinal muscular atrophy (SMA).

The data, which are drawn from a range of studies, are being presented virtually after the 2020 MDA Annual Conference was cancelled, due to the recent COVID-19 outbreak.

Novartis (NOVN: VX) company AveXis presented the data, which includes patients treated pre-symptomatically, and showed sustained durability in patients now up to five years post-dosing and some patients more than five years of age.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology